Not Applicable.

Uses and Use Restrictions

Funds for this program are to be used to implement and evaluate evidence-based strategies to address the challenges and systemic barriers that contribute to prevention and management of cardiovascular disease and diabetes in high-burden populations.

Eligibility Requirements

Applicant Eligibility

State Governments or their Bona Fide Agents (includes the District of Columbia) are eligible.

Beneficiary Eligibility

Beneficiaries of this program include: State, Local, Individual/Family, Minority Group, Anyone/General Public, Black American, American Indian, Spanish Origin, Oriental, Other Nonwhite, Women, Handicapped, Physically Afflicted, Senior Citizen, Rural.

Credentials/Documentation

No Credentials or documentation are required. This program is excluded from coverage under 2 CFR 200, Subpart E - Cost Principles.

Aplication and Award Process

Preapplication Coordination

Preapplication coordination is required.

Environmental impact information is not required for this program.

This program is eligible for coverage under E.O.

12372, 'Intergovernmental Review of Federal Programs.' An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.

Application Procedures

2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program.

Award Procedures

Review and Selection Process: Applications will be reviewed in three phases. Phase I Review: All applications will be reviewed initially for completeness by CDC OGS staff and will be reviewed jointly for eligibility by the CDC National Center for Chronic Disease Prevention and Health Promotion and CDC OGS. Incomplete applications that do not meet the eligibility criteria will not advance to Phase II review. Phase II Review: This funding opportunity is comprised of two components ? Component 1 and Component 2. Applications submitted under Component 1 are non-competitive and will support the implementation and evaluation of a core set of evidence-based strategies defined to reduce risk, complications, and/or barriers to prevent and control diabetes and cardiovascular disease among high-burden populations in all states and the District of Columbia. Applications submitted under Component 2 will be competitive and will support the implementation and evaluation of work on a small set of innovative strategies designed to reduce risks, complications, and/or barriers to prevent and control diabetes and prevention of heart disease and stroke. Component 2 applications will undergo an objective review panel process to evaluate complete and responsiveness according to the criteria section of the funding opportunity. Phase III Review: Applications submitted under Component 1 will be funded in accordance with the number of strategies selected by applicants from each of the diabetes and heart disease so that investments and outcomes may be clearly identified by funding line. Applications submitted under Component 2 will be funded in order by score and rank determined by the objective review panel. The Selecting official shall rely on the rank order established by the objective review panel as the primary factor in making awards.

Deadlines

Contact the headquarters or regional office, as appropriate, for application deadlines.

Authorization

Section 301(a) of the Public Health Service Act [42] U.S.C. Section 241(a) Title IV Section 4002 of the Affordable Care Action, Prevention and Public Health Fund.

Range of Approval/Disapproval Time

From 120 to 180 days. .Applications will be evaluated and approved or disapproved within 180 days of submission to the Federal Agency.

Appeals

Not Applicable.

Renewals

> 180 Days. .Renewals are contingent on availability of funds and are awarded for a 12 budget period within a 5 year project period.

Assistance Considerations

Formula and Matching Requirements

This program has no statutory formula. This program has no matching requirements. This program does not have MOE requirements.

Length and Time Phasing of Assistance

Funding for this program will be awarded on annual basis and the funding will be available for obligation by recipients for a period of 12-months. Method of awarding/releasing assistance: lump sum.

Post Assistance Requirements

Reports

Awardees will be expected to provide reports so that CDC can provide continuous program monitoring.

These reports identify successes and challenges that awardees encounter throughout the project period.

Also, reporting is a requirement for awardees who want to apply for yearly continuation of funding.

Awardees will be expected to submit annual performance reports, ongoing performance measure data, administrative reports, and a final performance and financial report.

A detailed explanation of any additional reporting requirements will be provided in the notice of award to successful applicants.

No cash reports are required.

Progress reports are required on annual basis.

Awardees will submit Annual Federal Financial Reports using the SF-425.

These reports are required and must be submitted to the CDC Grants Management Officer no later than 90-days after the end of each budget period.

Annual performance progress and monitoring reports will be expected from all awardees no later than 120 days prior to the end of each budget period.

This report will serve as the continuation application for the follow-on budget period.

The contents of the report should include the information specified in the solicitation from the CDC Grants Management Officer.

Audits

This program is excluded from coverage under 2 CFR 200, Subpart F - Audit Requirements. Recipients are to follow HHS policy audit requirements per codified regulations.

Records

CDC requires awardees to meet all record retention requirements defined in the notice of award, the funding opportunity, the HHS grants policy statement, and 45 CFR Part 75.

Financial Information

Account Identification

75-0943-0-1-550.

Obigations

(Project Grants) FY 17 Not Available; FY 18 est $120,769,531; and FY 19 Estimate Not Available

Range and Average of Financial Assistance

Awards ranged from $980,000 to $3,800,000. Awards we based on per-capita population and the burden of disease of diabetes and heart disease and stroke in each individual state.

Regulations, Guidelines, and Literature

Not Applicable.

Information Contacts

Regional or Local Office

None.

Headquarters Office

Robert Hancock 4770 Buford Highway, MS F75, Atlanta, Georgia 30341 Email: rnh2@cdc.gov Phone: 7704881431

Criteria for Selecting Proposals

Review and Selection Process: Applications will be reviewed in three phases. Phase I Review: All applications will be reviewed initially for completeness by CDC OGS staff and will be reviewed jointly for eligibility by the CDC National Center for Chronic Disease Prevention and Health Promotion and CDC OGS. Incomplete applications that do not meet the eligibility criteria will not advance to Phase II review. Phase II Review: This funding opportunity is comprised of two components ? Component 1 and Component 2. Applications submitted under Component 1 are non-competitive and will support the implementation and evaluation of a core set of evidence-based strategies defined to reduce risk, complications, and/or barriers to prevent and control diabetes and cardiovascular disease among high-burden populations in all states and the District of Columbia. Applications submitted under Component 2 will be competitive and will support the implementation and evaluation of work on a small set of innovative strategies designed to reduce risks, complications, and/or barriers to prevent and control diabetes and prevention of heart disease and stroke. Component 2 applications will undergo an objective review panel process to evaluate complete and responsiveness according to the criteria section of the funding opportunity. Phase III Review: Applications submitted under Component 1 will be funded in accordance with the number of strategies selected by applicants from each of the diabetes and heart disease so that investments and outcomes may be clearly identified by funding line. Applications submitted under Component 2 will be funded in order by score and rank determined by the objective review panel. The Selecting official shall rely on the rank order established by the objective review panel as the primary factor in making awards.